Verastem, Inc. (VSTM) stock
VSTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$8.18−0.26 (-3.08%)
Close on Nov 13, 2026Market cap $740.81MP/E –Yield –
Verastem EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Verastem's EPS for the twelve months ending Sep 30, 2026 was -$1.94. For fiscal 2025 it was -$3.02. The highest annual figure on record is -$3.02 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$3.02 | – |
| FY2024 | Dec 31, 2024 | -$3.66 | – |
| FY2023 | Dec 31, 2023 | -$3.96 | – |
| FY2022 | Dec 31, 2022 | -$4.57 | – |
| FY2021 | Dec 31, 2021 | -$4.90 | – |
| FY2020 | Dec 31, 2020 | -$5.28 | – |
| FY2019 | Dec 31, 2019 | -$24.00 | – |
| FY2018 | Dec 31, 2018 | -$16.44 | – |
| FY2017 | Dec 31, 2017 | -$21.12 | – |
| FY2016 | Dec 31, 2016 | -$11.88 | – |
| FY2015 | Dec 31, 2015 | -$19.32 | – |
| FY2014 | Dec 31, 2014 | -$24.84 | – |
| FY2013 | Dec 31, 2013 | -$21.84 | – |
| FY2012 | Dec 31, 2012 | -$20.40 | – |
| FY2011 | Dec 31, 2011 | -$127.08 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.74 | – |
| Q2 FY2026 | Jun 30, 2026 | -$0.35 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.46 | – |
| Q4 FY2025 | Dec 31, 2025 | -$0.39 | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.35 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.62 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.96 | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.32 | – |
| Q1 FY2024 | Jun 30, 2024 | -$1.57 | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.02 | – |
| Q3 FY2023 | Sep 30, 2023 | -$0.75 | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.37 | – |
| Q1 FY2023 | Mar 31, 2023 | -$0.08 | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.08 | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.44 | – |
| Q1 FY2022 | Mar 31, 2022 | -$0.09 | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.14 | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.56 | -262.5% |
| Q2 FY2021 | Jun 30, 2021 | -$1.20 | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.08 | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.44 | – |
| Q3 FY2020 | Sep 30, 2020 | $0.96 | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.68 | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.20 | – |
| Q4 FY2019 | Dec 31, 2019 | -$6.12 | – |
| Q3 FY2019 | Sep 30, 2019 | -$4.92 | – |
| Q2 FY2019 | Jun 30, 2019 | -$6.84 | – |
| Q1 FY2019 | Mar 31, 2019 | -$6.24 | – |
| Q4 FY2018 | Dec 31, 2018 | -$4.44 | – |
| Q3 FY2018 | Sep 30, 2018 | -$3.48 | – |
| Q2 FY2018 | Jun 30, 2018 | -$3.60 | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.92 | – |
| Q4 FY2017 | Dec 31, 2017 | -$5.16 | – |
| Q3 FY2017 | Sep 30, 2017 | -$7.32 | – |
| Q2 FY2017 | Jun 30, 2017 | -$4.32 | – |
| Q1 FY2017 | Mar 31, 2017 | -$4.20 | – |
| Q4 FY2016 | Dec 31, 2016 | -$3.84 | – |
| Q3 FY2016 | Sep 30, 2016 | -$2.52 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?